ZS Pharma Inc Company News


Old Arcived News About ZS Pharma Inc

  • Actelion says selexipag to enter U.S. market in January. [Reuters] - Actelion Ltd has received approval from the U.S. Food and Drug Administration to bring its pulmonary arterial hypertension drug selexipag, or Uptravi, to the market. The Swiss company said selexipag, indicated ...
  • AstraZeneca completes acquisition of ZS Pharma. [at noodls] - AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced ...
  • AstraZeneca confirms interest in a possible $5B purchase.
  • Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio.
  • INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ZS Pharma, Inc. And Encourages Shareholders To Contact The Firm For Additional Information. [Business Wire] - The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of ZS Pharma, Inc.
  • INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ZS Pharma, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to AstraZeneca PLC -- ZSPH. [PR Newswire] - NEW YORK, Nov. 13, 2015 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased ZS Pharma, Inc. (NASDAQGM: ZSPH) stock prior to November ...
  • Market Isn’t Sure What to Make of Blowout Jobs Report.
  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ZS Pharma, Inc. of an Investigation In Connection With the Fairness of the Sale of the Company to AstraZeneca PLC -- ZSPH. [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 11, 2015 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased ZS Pharma, Inc. (NASDAQGM: ZSPH) stock prior ...
  • Should You Avoid Abengoa Yield PLC.
  • Stock Futures Struggle for Direction After Blowout Jobs.
  • Stocks Are Lower as Chances of December Hike Grow.
  • ZS Pharma (ZSPH) Stock Gets Rating Downgrade at Credit Suisse.
  • ZS Pharma (ZSPH) Stock Skyrockets on AstraZeneca Merger.
  • ZS Pharma Announces New Employment Inducement Grants. [at noodls] - SAN MATEO, Calif., Dec. 9, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq:SPH), today announced that on December 7, 2015 the compensation committee of its board of directors granted stock options to ...
  • ZS Pharma Inc.
  • ZS PHARMA, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur.
  • ZS PHARMA, INC. Financials.
  • ZS PHARMA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with AstraZeneca PLC. [Business Wire] - Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of ZS Pharma, Inc.

ZS Pharma Inc Short Company Overview:

ZS Pharma, Inc. develops and distributes specialty pharmaceutical products. The Company produces non-absorbed drugs to treat cardiovascular, renal, liver and metabolic diseases. ZS Pharma offers its products to the medical and healthcare industries.